» Articles » PMID: 26235544

Sustained Biologic-free and Drug-free Remission in Rheumatoid Arthritis, Where Are We Now?

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2015 Aug 4
PMID 26235544
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The advent of new medications and new treatment strategies for rheumatoid arthritis has made it possible to achieve remission in more patients than before. Furthermore, recent clinical trials and register studies suggest that some patients who initially required aggressive therapy may achieve biologic-free remission or even the ultimate goal of therapy, drug-free remission, resembling recovery. Here, we present a discursive review of the most important studies addressing these issues. Based on the overall results, it remains unclear if achieving biologic-free and drug-free remissions are primarily due to the natural course of the disease or to the early therapeutic intervention according to the 'window of opportunity' hypothesis. Although medication-free remission is only achievable in a small subset of patients, characterizing this patient cohort may provide important information about beneficial prognostic factors and the underlying mechanisms. In summary, in a subset of patients biologic-free and even drug-free remission can be achieved; pursuing these possibilities in practice may decrease the risk for long-term side effects and attenuate the economic burden of the disease.

Citing Articles

CONTExT-RA: a cross-sectional study evaluating disease activity, quality of life and the socio-demographic profile of Irish patients with rheumatoid arthritis.

Murphy G, ORourke K, Camon A, Kane D, OShea F, Conway R Rheumatol Adv Pract. 2024; 8(4):rkae132.

PMID: 39588298 PMC: 11588026. DOI: 10.1093/rap/rkae132.


Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.

Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M RMD Open. 2024; 10(4).

PMID: 39448205 PMC: 11499799. DOI: 10.1136/rmdopen-2024-004727.


Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.

van Vollenhoven R, Hall S, Wells A, Meerwein S, Song Y, Tanjinatus O RMD Open. 2024; 10(3.

PMID: 39053948 PMC: 11284904. DOI: 10.1136/rmdopen-2023-004037.


Immunomodulatory Nanoparticles for Modulating Arthritis Flares.

Johnson W, McBride D, Kerr M, Nguyen A, Zoccheddu M, Bollmann M ACS Nano. 2023; 18(3):1892-1906.

PMID: 38016062 PMC: 11755865. DOI: 10.1021/acsnano.3c05298.


Reprogrammed siTNF/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy.

Chen Y, Li K, Jiao M, Huang Y, Zhang Z, Xue L Acta Pharm Sin B. 2023; 13(2):787-803.

PMID: 36873164 PMC: 9978920. DOI: 10.1016/j.apsb.2022.08.012.


References
1.
Gabriel S, Crowson C, OFallon W . Mortality in rheumatoid arthritis: have we made an impact in 4 decades?. J Rheumatol. 1999; 26(12):2529-33. View

2.
Baka Z, Buzas E, Nagy G . Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther. 2009; 11(4):238. PMC: 2745780. DOI: 10.1186/ar2751. View

3.
Quinn M, Emery P . Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2004; 21(5 Suppl 31):S154-7. View

4.
Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

5.
Quinn M, Conaghan P, OConnor P, Karim Z, Greenstein A, Brown A . Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a.... Arthritis Rheum. 2005; 52(1):27-35. DOI: 10.1002/art.20712. View